$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000071913521000064 Filed on August 12, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$11.22M	$4.296M
YoY Change	161.27%	-35.39%
Cost Of Revenue	$3.690M	$2.202M
YoY Change	67.57%	11.49%
Gross Profit	$7.534M	$2.094M
YoY Change	259.79%	-55.2%
Gross Profit Margin	67.12%	48.74%
Selling, General & Admin	$4.261M	$2.189M
YoY Change	94.66%	-27.92%
% of Gross Profit	56.56%	104.54%
Research & Development	$1.084M	$975.0K
YoY Change	11.18%	9.8%
% of Gross Profit	14.39%	46.56%
Depreciation & Amortization	$210.0K	$230.0K
YoY Change	-8.7%	76.92%
% of Gross Profit	2.79%	10.98%
Operating Expenses	$11.58M	$8.261M
YoY Change	40.14%	-9.18%
Operating Profit	-$4.043M	-$6.167M
YoY Change	-34.44%	39.46%
Interest Expense	$2.000K	$8.000K
YoY Change	-75.0%
% of Operating Profit
Other Income/Expense, Net	$99.00K	-$15.00K
YoY Change	-760.0%	-107.39%
Pretax Income	-$3.944M	-$6.182M
YoY Change	-36.2%	46.53%
Income Tax	$107.0K	-$1.492M
% Of Pretax Income
Net Earnings	-$4.046M	-$4.690M
YoY Change	-13.73%	8.11%
Net Earnings / Revenue	-36.05%	-109.17%
Basic Earnings Per Share	-$0.12	-$0.14
Diluted Earnings Per Share	-$0.12	-$0.14
COMMON SHARES
Basic Shares Outstanding	34.32M shares	34.19M shares
Diluted Shares Outstanding	34.32M shares	34.19M shares

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$34.67M	$46.20M
YoY Change	-24.96%	-31.45%
Cash & Equivalents	$34.67M	$46.16M
Short-Term Investments
Other Short-Term Assets	$3.615M	$4.000M
YoY Change	-9.63%	100.0%
Inventory	$5.272M	$5.257M
Prepaid Expenses
Receivables	$8.985M	$6.306M
Other Receivables	$1.386M	$1.671M
Total Short-Term Assets	$61.58M	$69.84M
YoY Change	-11.83%	-14.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.471M	$6.440M
YoY Change	0.48%	2.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.033M	$560.0K
YoY Change	84.46%	25.84%
Total Long-Term Assets	$8.015M	$7.986M
YoY Change	0.36%	15.3%
TOTAL ASSETS
Total Short-Term Assets	$61.58M	$69.84M
Total Long-Term Assets	$8.015M	$7.986M
Total Assets	$69.60M	$77.83M
YoY Change	-10.57%	-12.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.799M	$2.206M
YoY Change	26.88%	34.43%
Accrued Expenses	$5.963M	$6.911M
YoY Change	-13.72%	18.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$225.0K	$400.0K
YoY Change	-43.75%
Total Short-Term Liabilities	$10.75M	$9.635M
YoY Change	11.52%	22.01%
LONG-TERM LIABILITIES
Long-Term Debt	$76.00K	$400.0K
YoY Change	-81.0%	300.0%
Other Long-Term Liabilities	$145.0K	$765.0K
YoY Change	-81.05%	155.0%
Total Long-Term Liabilities	$145.0K	$765.0K
YoY Change	-81.05%	91.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.75M	$9.635M
Total Long-Term Liabilities	$145.0K	$765.0K
Total Liabilities	$11.92M	$10.99M
YoY Change	8.41%	32.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$6.326M	$7.876M
YoY Change	-180.32%	-67.62%
Common Stock	$34.00K	$34.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$57.36M	$66.84M
YoY Change
Total Liabilities & Shareholders Equity	$69.60M	$77.83M
YoY Change	-10.57%	-12.44%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$4.046M	-$4.690M
YoY Change	-13.73%	8.11%
Depreciation, Depletion And Amortization	$210.0K	$230.0K
YoY Change	-8.7%	76.92%
Cash From Operating Activities	-$5.008M	-$5.020M
YoY Change	-0.24%	-10.2%
INVESTING ACTIVITIES
Capital Expenditures	-$31.00K	-$90.00K
YoY Change	-65.56%	-77.5%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$31.00K	-$90.00K
YoY Change	-65.56%	-100.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	156.0K	-70.00K
YoY Change	-322.86%	-240.0%
NET CHANGE
Cash From Operating Activities	-5.008M	-5.020M
Cash From Investing Activities	-31.00K	-90.00K
Cash From Financing Activities	156.0K	-70.00K
Net Change In Cash	-4.883M	-5.180M
YoY Change	-5.73%	-114.83%
FREE CASH FLOW
Cash From Operating Activities	-$5.008M	-$5.020M
Capital Expenditures	-$31.00K	-$90.00K
Free Cash Flow	-$4.977M	-$4.930M
YoY Change	0.95%	-5.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000719135
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-12183
	dei	Entity Registrant Name EntityRegistrantName	APYX MEDICAL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2644611
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5115 Ulmerton Road,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Clearwater
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33760
	dei	City Area Code CityAreaCode	727
	dei	Local Phone Number LocalPhoneNumber	384-2323
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	APYX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34322749	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34670000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41915000	USD
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	340000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8985000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8399000	USD
CY2021Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7654000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7654000	USD
CY2021Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1386000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1275000	USD
CY2021Q2	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	387000	USD
CY2020Q4	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	388000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	5272000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4051000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3615000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2795000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	61582000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	66089000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5120000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4813000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6471000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6541000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	182000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	237000	USD
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	329000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	437000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1033000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	807000	USD
CY2021Q2	us-gaap	Assets Assets	69597000	USD
CY2020Q4	us-gaap	Assets Assets	74111000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2799000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1511000	USD
CY2021Q2	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7594000	USD
CY2020Q4	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7278000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	126000	USD
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	225000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	238000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10745000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9153000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	63000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129000	USD
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	76000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	183000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	886000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	621000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	145000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	166000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	11915000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	10252000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34322749	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34322749	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34289222	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34289222	shares
	us-gaap	Professional Fees ProfessionalFees	4047000	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	63650000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61066000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6326000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2621000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	57358000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	63721000	USD
CY2021Q2	us-gaap	Minority Interest MinorityInterest	324000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	138000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57682000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63859000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	69597000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74111000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11224000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4296000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19862000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9293000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3690000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2202000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6468000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4215000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	7534000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	2094000	USD
	us-gaap	Gross Profit GrossProfit	13394000	USD
	us-gaap	Gross Profit GrossProfit	5078000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1084000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	975000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2199000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1955000	USD
CY2021Q2	us-gaap	Professional Fees ProfessionalFees	1889000	USD
CY2020Q2	us-gaap	Professional Fees ProfessionalFees	1658000	USD
	us-gaap	Professional Fees ProfessionalFees	3410000	USD
CY2021Q2	us-gaap	Salaries And Wages SalariesAndWages	4343000	USD
CY2020Q2	us-gaap	Salaries And Wages SalariesAndWages	3439000	USD
	us-gaap	Salaries And Wages SalariesAndWages	8588000	USD
	us-gaap	Salaries And Wages SalariesAndWages	6750000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4261000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2189000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7985000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5985000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	11577000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	8261000	USD
	us-gaap	Operating Expenses OperatingExpenses	22182000	USD
	us-gaap	Operating Expenses OperatingExpenses	18737000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4043000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6167000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8788000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13659000	USD
CY2021Q2	us-gaap	Interest Income Operating InterestIncomeOperating	4000	USD
CY2020Q2	us-gaap	Interest Income Operating InterestIncomeOperating	7000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	7000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	223000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	2000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	8000	USD
	us-gaap	Interest Expense InterestExpense	6000	USD
	us-gaap	Interest Expense InterestExpense	14000	USD
CY2021Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	97000	USD
CY2020Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-14000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	4000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	412000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	99000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	621000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3944000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6182000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8783000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13038000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1492000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	173000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6397000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-4051000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-4690000	USD
	us-gaap	Profit Loss ProfitLoss	-8956000	USD
	us-gaap	Profit Loss ProfitLoss	-6641000	USD
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5000	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-9000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4046000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4690000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8947000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6641000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70429000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1097000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-4690000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66836000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	60169000	USD
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	195000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1369000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-4051000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57682000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71259000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	72000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2146000	USD
	us-gaap	Profit Loss ProfitLoss	-6641000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66836000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63859000	USD
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	195000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2563000	USD
	us-gaap	Profit Loss ProfitLoss	-8956000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57682000	USD
	us-gaap	Profit Loss ProfitLoss	-8956000	USD
	us-gaap	Profit Loss ProfitLoss	-6641000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	440000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	439000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2563000	USD
	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	13000	USD
	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	413000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2146000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	46000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	486000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	656000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1195000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1160000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1410000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	6017000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1198000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	571000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1296000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-232000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	554000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2241000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7058000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12433000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	221000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	184000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-221000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-184000	USD
	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	21000	USD
	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	72000	USD
	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	120000	USD
	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	120000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	195000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	96000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-48000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-62000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12656000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41915000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58812000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7245000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34670000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46156000	USD
	us-gaap	Interest Paid Net InterestPaidNet	4000	USD
	us-gaap	Interest Paid Net InterestPaidNet	8000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	13000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	54000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior year to conform to the current year presentation. These reclassifications had no impact on previously reported net income, retained earnings or operating cash flows for the periods presented.</span></div>
CY2018Q3	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	97000000	USD
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	3226000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2243000	USD
CY2021Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1167000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1109000	USD
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1266000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1087000	USD
CY2021Q2	us-gaap	Inventory Gross InventoryGross	5659000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	4439000	USD
CY2021Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	387000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	388000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	5272000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4051000	USD
CY2021Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1016000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	808000	USD
CY2021Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	996000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	811000	USD
CY2021Q2	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	730000	USD
CY2020Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1001000	USD
CY2021Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	527000	USD
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	498000	USD
CY2021Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	405000	USD
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	435000	USD
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	357000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	222000	USD
CY2021Q2	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1027000	USD
CY2020Q4	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1027000	USD
CY2021Q2	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	1758000	USD
CY2020Q4	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	1658000	USD
CY2021Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	173000	USD
CY2020Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	591000	USD
CY2021Q2	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	605000	USD
CY2020Q4	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	227000	USD
CY2021Q2	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7594000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7278000	USD
CY2019Q4	apyx	Noncontrolling Interest Required Capital Contribution NoncontrollingInterestRequiredCapitalContribution	357000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4046000	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4046000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4690000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4690000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8947000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8947000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6641000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6641000	USD
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34321000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34321000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34186000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34186000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34312000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34312000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34181000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34181000	shares
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1369000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2563000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1097000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2146000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4938943	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	775980	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.32
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	55582	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.56
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	98635	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.05
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5560706	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.96
CY2021Q2	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	6614	shares
CY2020Q2	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	11085	shares
CY2021Q2	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	4886	shares
CY2020Q2	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	17665	shares
	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	22055	shares
	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	13009	shares
	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	26027	shares
	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	22027	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	apyx	Cares Act Income Tax Expense Benefit Release Of Valuation Allowance Federal Net Operating Loss Carryforwards CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards	-3700000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1500000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6400000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1492000	USD
CY2021Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.027
CY2020Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.241
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	173000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6397000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.020
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.491
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1313000	USD
CY2021Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	445000	USD
CY2021Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	51000	USD
CY2020Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	43000	USD
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	99000	USD
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	86000	USD
CY2021Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1758000	USD
CY2021Q2	us-gaap	Purchase Obligation PurchaseObligation	2300000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11224000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4043000	USD
CY2021Q2	us-gaap	Interest Income Operating InterestIncomeOperating	4000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	2000	USD
CY2021Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	97000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4296000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6167000	USD
CY2020Q2	us-gaap	Interest Income Operating InterestIncomeOperating	7000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	8000	USD
CY2020Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-14000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1492000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19862000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8788000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	7000	USD
	us-gaap	Interest Expense InterestExpense	6000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	4000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	173000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9293000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13659000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	223000	USD
	us-gaap	Interest Expense InterestExpense	14000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	412000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6397000	USD
CY2021Q2	apyx	Total Revenue Percent TotalRevenuePercent	0.342
	apyx	Total Revenue Percent TotalRevenuePercent	0.348
CY2020Q2	apyx	Total Revenue Percent TotalRevenuePercent	0.210
	apyx	Total Revenue Percent TotalRevenuePercent	0.246
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11224000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4296000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19862000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9293000	USD

Files In Submission

Name	View Source	Status
0000719135-21-000064-index-headers.html	Edgar Link	pending
0000719135-21-000064-index.html	Edgar Link	pending
0000719135-21-000064.txt	Edgar Link	pending
0000719135-21-000064-xbrl.zip	Edgar Link	pending
a2021q210-qexhibit311.htm	Edgar Link	pending
a2021q210-qexhibit312.htm	Edgar Link	pending
a2021q210-qexhibit321.htm	Edgar Link	pending
a2021q210-qexhibit322.htm	Edgar Link	pending
apyx-20210630.htm	Edgar Link	pending
apyx-20210630.xsd	Edgar Link	pending
apyx-20210630_cal.xml	Edgar Link	unprocessable
apyx-20210630_def.xml	Edgar Link	unprocessable
apyx-20210630_g1.jpg	Edgar Link	pending
apyx-20210630_htm.xml	Edgar Link	completed
apyx-20210630_lab.xml	Edgar Link	unprocessable
apyx-20210630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2021 Q2 Form 10-Q Financial Statement

#000071913521000064 Filed on August 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2021 Q2 Form 10-Q Financial Statement

#000071913521000064 Filed on August 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx